Abstract:Introduction: Fibroblast growth factor receptor 3 (FGFR3) is a tyrosine kinase membrane-spanning protein whose function is to regulate chondrocyte proliferation, differentiation and matrix production during cartilage development. Several mutations in FGFR3 have now been documented to link to human diseases. A number of these mutations result in constitutive activation of the FGFR3, leading to proliferation and premature differentiation of chondrocytes. Depending on the mutation and the resultant level of FGFR3 activation, mild to severe skeletal dysplasias such as achondroplasia (ACH), hypochondroplasia (HCH), thanatophoric dysplasia type I (TDI) and type II (TDII), and severe achondroplasia with developmental delay and acanthosis nigrans (SADDAN) may result. It has been postulated that the signalling pathways downstream of FGFR3 may be responsible for activating transcription factors, leading to up-regulation of cell cycle inhibitors and causing abnormal suppression of chondrocyte cell proliferation. However, the precise signalling pathways involved in FGFR3 mutation have as yet to be elucidated. The aim of this study was to investigate and compare the differences in the downstream signalling pathways between FGFR3 mutants. Methods and Results: Wild type FGFR3 has been cloned into expression vector pcDNA3 and the construct has been used to generate four different FGFR3 mutants using site-directed mutagenesis. The mutations which have been introduced and the types of dysplasia they correspond to were as follows: K380R (ACH), N540K (HCH) and K650E (TDII). A kinase dead form of the receptor, K504R has also been generated. Wild type and each of the four mutant FGFR3 proteins in pcDNA3 vector have been successfully transfected into 293T cells using the calcium phosphate method. Immunoprecipitation and Western Blot analysis of cell lysates revealed expression of wild type protein in three isoforms of size 135kDa (mature), 120kDa (intermediate) and 98kDa (immature). The mutant proteins all followed a similar pattern of expression with the exception of the TDII mutant that did not express the mature form of the FGFR3. Changes in MAPK, PLCa and STAT 1 signalling pathways in response to FGFs-1, 2, 9 and 18 in the 293-cells of wild type and mutant forms of FGFR3 are now under investigation, in an attempt to define which pathways are mostly responsible for the resultant abnormal phenotypes. Discussion: Genomics studies have demonstrated that FGFR3 expression is significantly upregulated during the osteoblastic differentiation of mesenchymal stem cells (MSCs) under BMP-2 stimulation in vitro. Subsequent functional studies have demonstrated that a selective ligand for FGFR3, FGF9, is able to induce tyrosine kinase signalling, and the osteoblastic differentiation of MSCs in vitro. Further understanding the signalling mechanisms of FGFR3 activation in normal and mutant forms may lead to discover potential anabolic agents that are based on FGFR3-FGFs pathways.

Highly Activated Fgfr3 with the K644M Mutation Causes Prolonged Survival in Severe Dwarf Mice

A Lys644Glu Substitution in Fibroblast Growth Factor Receptor 3 (FGFR3) Causes Dwarfism in Mice by Activation of STATs and Ink4 Cell Cycle Inhibitors.

Gly369Cys Mutation in Mouse FGFR3 Causes Achondroplasia by Affecting Both Chondrogenesis and Osteogenesis.

A Neonatal Lethal Mutation in FGFR3 Uncouples Proliferation and Differentiation of Growth Plate Chondrocytes in Embryos.

Mutant <i>B3GALT6</i> in a Multiplex Family: A Dominant Variant Co-Segregated With Moderate Malformations

A Ser(365)-->Cys Mutation of Fibroblast Growth Factor Receptor 3 in Mouse Downregulates Ihh/PTHrP Signals and Causes Severe Achondroplasia.

Mouse Models Orthologous to FGFR3-related Skeletal Dysplasias.

Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism

Defective Joint Development and Maintenance in <i>GDF6</i>-Related Multiple Synostoses Syndrome

[Gly374arg Mutation in Fgfr3 Causes Achondroplasia in Mice].

MLK3 Regulates Bone Development Downstream of the Faciogenital Dysplasia Protein FGD1 in Mice.

FGD1 Variant Associated with Aarskog–Scott Syndrome

Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.

FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3): COMPARISON OF THE SIGNALLING PATHWAYS ACTIVATED BY THE WILD TYPE AND ITS MUTANT RECEPTORS

Expression of an Active Gαs Mutant in Skeletal Stem Cells is Sufficient and Necessary for Fibrous Dysplasia Initiation and Maintenance

Soluble Form of FGFR2 with S252W Partially Prevents Craniosynostosis of the Apert Mouse Model

Mutations That Cause Osteoglophonic Dysplasia Define Novel Roles for Fgfr1 in Bone Elongation

Autoinhibitory Mechanism for the Mutation-Induced Impaired FGF9 Signaling.

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Motor deficits in fibroblast growth factor receptor-3 null mutant mice.

Defective Lysosomal Targeting of Activated Fibroblast Growth Factor Receptor 3 in Achondroplasia.